Bcr-Abl T315I inhibitor (Hanmi)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameBcr-Abl T315I inhibitor (Hanmi)
Drug Alias NameHM-95091HM-95175
ClassificationSmall molecules
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsAnticancer protein kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHanmi Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A